HXR9 treatment results in the downregulation of miR-221&222 in human melanoma cells as a consequence of HOXB7/PBX2 heterodimer disruption and the subsequent degradation of HOXB7 and PBX2 proteins. Here, PBX2 is linked to melanoma.